Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Change in Receivables (2023 - 2025)

Bioregenx's Change in Receivables history spans 3 years, with the latest figure at -$22892.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$22892.0 for Q4 2025, down 414.43% from a year ago — trailing twelve months through Dec 2025 was $24726.0 (up 127.6% YoY), and the annual figure for FY2025 was $24726.0, up 127.6%.
  • Change in Receivables for Q4 2025 was -$22892.0 at Bioregenx, down from $41495.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $41495.0 in Q3 2025 to a low of -$93406.0 in Q1 2024.
  • The 3-year median for Change in Receivables is $605.0 (2023), against an average of -$3643.4.
  • The sharpest move saw Change in Receivables tumbled 482.15% in 2024, then skyrocketed 4393.1% in 2025.
  • Year by year, Change in Receivables stood at $22584.0 in 2023, then tumbled by 119.7% to -$4450.0 in 2024, then tumbled by 414.43% to -$22892.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$22892.0, $41495.0, and $9960.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.